The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658)
in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51.
Additional objectives include evaluation of safety, biomarkers and the long-term effects of
eteplirsen up to 96 weeks, followed by a safety extension (not to exceed 48 weeks).